The role of FXYD3 in malignancy has been investigated in a variety of cancers, including esophageal squamous cell carcinoma [25], gastric cancer [26], endometrial cancer [8], pancreatic cancer [27], breast cancer [28,29,30], hepatocellular carcinoma [13], glioma [31], lung cancer [32], and colorectal carcinoma [10,11,12,33,34,35]. Here, FXYD3 is linked to lung cancer.